RXO Inc. reported a strong 25% year-over-year revenue increase to $1.77 billion but did not achieve earnings growth, with gross margins falling from 21.2% to 17%. The company faces margin compression, negative operating cash flow, and rising long-term debt, signaling weakening fundamentals. Despite optimistic forward earnings per share forecasts and bullish market sentiment, RXO's high valuation multiples (33x EV/EBITDA and 164x forward P/E) appear unsustainable. These structural challenges and financial strains led to a Sell rating, outweighing short-term gains from spot market conditions.
BMO Capital initiated coverage on Tenet Healthcare with a 'Market Perform' rating, indicating the stock is expected to perform in line with the broader market. The company is forecasted to report a 24.05% increase in Earnings Per Share (EPS) to $4.59...
Jaguar Health (JAGX) surged over 1,150% after the FDA granted fee waivers for its drugs Mytesi and Canalevia-CA1, signaling regulatory support. Greenland Mines (GRML) rose nearly 50% amid growing investor interest linked to U.S.-Greenland security de...
The market experienced a downturn with significant losses among key stocks. New Fortress Energy dropped 24.7% amid ongoing volatility in energy sectors, while Xanadu Quantum Technologies fell 21.7% reflecting sensitivity in quantum stocks to commerci...
Jefferies maintains a Hold rating on Capri Holdings due to uncertainty over a potential takeover. Despite a flat global luxury market, Capri's management expects growth in the second half of 2026, driven by new product launches, increased marketing, ...
Avalanche (AVAX) surged 55% in a week following the launch of Bitwise's Avalanche ETF (BAVA), the first regulated fund offering direct exposure to AVAX tokens with an active staking model. The ETF stakes about 70% of its holdings to generate an estim...
